Clinical Impact of MRD Monitoring in Elderly Patients with MM

Conference Correspondent  - Conference Correspondent, ASH

In multiple myeloma (MM), there is a growing body of evidence showing the importance of minimal residual disease (MRD) monitoring, particularly among transplant-ineligible patients. Paiva and colleagues assessed the clinical relevance of MRD monitoring in 163 elderly MM patients enrolled in the PETHEMA/GEM2010MAS65 trial of sequential bortezomib/melphalan/prednisone (VMP) followed by a lenalidomide/low-dose dexamethasone (Rd) regimen for 9 cycles each, or alternating cycles of VMP and Rd up to 18 cycles.1 MRD negativity was defined as <20 clonal plasma cells detected among ≥2,000,000 leukocytes (<0.001%; limit of detection: 10-5) using an 8-color second-generation flow assay.  

At a median follow-up of 3 years, there was no difference in MRD-negative rates between the sequential and alternating regimens (20% vs 24%; P = .37) at cycle 9. Patients attaining MRD negativity at cycle 9 demonstrated a significant prolongation in time to progression (TTP; median: not reached [NR] vs 35 months; P = .001), which translated to overall survival (OS) improvement (100% vs 68% at 2 years; P = .01) compared with those with persistent MRD. MRD persistence at cycle 9 in patients who achieved complete response (CR; n = 43) was associated with significantly inferior OS (100% vs 74% at 3 years; P = .02). Among patients with paired MRD assessments at cycles 9 and 18, 19% of MRD-positive patients at cycle 9 became MRD-negative at cycle 18, whereas all MRD-negative patients at cycle 9 remained negative at cycle 18. At the end of cycle 18 (n = 119), MRD-negative rates were numerically higher in the sequential treatment cohort (46% vs 33%; P = .19). Patients who achieved CR plus MRD negativity at cycle 9 showed significantly longer TTP compared with those with CR and MRD-positive disease (NR vs 42 months). When the impact of MRD negativity was assessed among patients with standard- and high-risk cytogenetics, those who achieved MRD negativity showed significantly prolonged TTP versus MRD-positive patients regardless of whether they had standard-risk (median, 40 months vs 31 months; P = .002) or high-risk (median, NR vs 26 months; P = .007) cytogenetics. However, the benefit was greater for the high-risk cytogenetics group. When assessed by patient age, patients who achieved MRD negativity showed improved survival outcomes regardless of age, but those with MRD positivity showed significantly decreased survival with increasing age (65-75 years: 32 months; 75-80 years: 28 months; >80 years: 22 months; P <.001). Based on these results, it was concluded that MRD negativity in elderly MM patients translated to significant improvements in survival irrespective of patients’ age and cytogenetic risk. Conversely, patients with standard-risk MM and those in complete remission but remaining MRD-positive experience poorer clinical outcomes and warrant individualization of their treatment to improve their survival.

  1. Paiva B, et al. ASH 2015. Abstract 4181.
Related Items
No Link between Long-Term Eltrombopag Treatment and Incidence of Cataracts in Adult Patients with Chronic ITP During EXTEND
Conference Correspondent  published on December 27, 2017 in ASH
Eltrombopag Treatment Improved Platelet Counts in Patients with Persistent or Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Fostamatinib-Treated Patients with Persistent/Chronic ITP Maintained Long-Term Responses
Conference Correspondent  published on December 27, 2017 in ASH
Avatrombopag Superior to Placebo for the Treatment of Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Subcutaneous Romiplostim Increased Platelet Response in Children with ITP
Conference Correspondent  published on December 27, 2017 in ASH
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Graft-versus-Host Disease: Breakthroughs on the Horizon
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Basket Clinical Trials: A New Era in Cancer Treatment
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Last modified: December 5, 2017